Literature DB >> 15178637

Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein.

Joshua A Beckman1, James K Liao, Shauna Hurley, Leslie A Garrett, Daoshan Chui, Debi Mitra, Mark A Creager.   

Abstract

Cigarette smoking impairs endothelial function. Hydroxymethylglutaryl (HMG) CoA reductase inhibitors (statins) may favorably affect endothelial function via nonlipid mechanisms. We tested the hypothesis that statins would improve endothelial function independent of changes in lipids in cigarette smokers. Twenty normocholesterolemic cigarette smokers and 20 matched healthy control subjects were randomized to atorvastatin 40 mg daily or placebo for 4 weeks, washed out for 4 weeks, and then crossed-over to the other treatment. Baseline low-density lipoprotein (LDL) levels were similar in smokers and healthy subjects, 103+/-22 versus 95+/-27 mg/dL, respectively (P=NS) and were reduced similarly in smokers and control subjects by atorvastatin, to 55+/-30 and 58+/-20 mg/dL, respectively (P=NS). Vascular ultrasonography was used to determine brachial artery, flow-mediated, endothelium-dependent, and nitroglycerin-mediated, endothelium-independent vasodilation. To elucidate potential molecular mechanisms that may account for changes in endothelial function, skin biopsy specimens were assayed for eNOS mRNA, eNOS activity, and nitrotyrosine. Endothelium-dependent vasodilation was less in smokers than nonsmoking control subjects during placebo treatment, 8.0+/-0.6% versus 12.1+/-1.1%, (P=0.003). Atorvastatin increased endothelium-dependent vasodilation in smokers to 10.5+/-1.3% (P=0.017 versus placebo) but did not change endothelium-dependent vasodilation in control subjects (to 11.0+/-0.8%, P=NS). Endothelium-independent vasodilation did not differ between groups during placebo treatment and was not significantly affected by atorvastatin. Multivariate analysis did not demonstrate any association between baseline lipid levels or the change in lipid levels and endothelium-dependent vasodilation. Cutaneous nitrotyrosine levels and skin microvessel eNOS mRNA, but not ENOS activity, were increased in smokers compared with controls but unaffected by atorvastatin treatment. Atorvastatin restores endothelium-dependent vasodilation in normocholesterolemic cigarette smokers independent of changes in lipids. These results are consistent with a lipid-independent vascular benefit of statins but could not be explained by changes in eNOS message and tissue oxidative stress. These findings implicate a potential role for statin therapy to restore endothelial function and thereby investigate vascular disease in cigarette smokers.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15178637      PMCID: PMC2633456          DOI: 10.1161/01.RES.0000134628.96682.9b

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  50 in total

1.  Tetrahydrobiopterin restores endothelial function in long-term smokers.

Authors:  S Ueda; H Matsuoka; H Miyazaki; M Usui; S Okuda; T Imaizumi
Journal:  J Am Coll Cardiol       Date:  2000-01       Impact factor: 24.094

2.  Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.

Authors:  A H Wagner; T Köhler; U Rückschloss; I Just; M Hecker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-01       Impact factor: 8.311

3.  Oral vitamin C and endothelial function in smokers: short-term improvement, but no sustained beneficial effect.

Authors:  O T Raitakari; M R Adams; R J McCredie; K A Griffiths; R Stocker; D S Celermajer
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

4.  Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases.

Authors:  H Zhang; A Schmeisser; C D Garlichs; K Plötze; U Damme; A Mügge; W G Daniel
Journal:  Cardiovasc Res       Date:  1999-10       Impact factor: 10.787

5.  Superoxide anion scavenging properties of fluvastatin and its metabolites.

Authors:  K Suzumura; M Yasuhara; H Narita
Journal:  Chem Pharm Bull (Tokyo)       Date:  1999-10       Impact factor: 1.645

6.  Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers : evidence for a dysfunctional nitric oxide synthase.

Authors:  T Heitzer; C Brockhoff; B Mayer; A Warnholtz; H Mollnau; S Henne; T Meinertz; T Münzel
Journal:  Circ Res       Date:  2000-02-04       Impact factor: 17.367

7.  Neuroprotection mediated by changes in the endothelial actin cytoskeleton.

Authors:  U Laufs; M Endres; N Stagliano; S Amin-Hanjani; D S Chui; S X Yang; T Simoncini; M Yamada; E Rabkin; P G Allen; P L Huang; M Böhm; F J Schoen; M A Moskowitz; J K Liao
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

8.  3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1).

Authors:  U Laufs; D Marra; K Node; J K Liao
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

9.  Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function.

Authors:  S Milstien; Z Katusic
Journal:  Biochem Biophys Res Commun       Date:  1999-10-05       Impact factor: 3.575

10.  Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells.

Authors:  Y Su; W Han; C Giraldo; Y De Li; E R Block
Journal:  Am J Respir Cell Mol Biol       Date:  1998-11       Impact factor: 6.914

View more
  27 in total

1.  Endothelium-dependent vasodilation is associated with exercise capacity in smokers and non-smokers.

Authors:  Kevin S Heffernan; Richard H Karas; Eshan A Patvardhan; Jeffrey T Kuvin
Journal:  Vasc Med       Date:  2010-04       Impact factor: 3.239

2.  New Member of Endothelial Arsenal Against Inflammation.

Authors:  Walter N Durán; Fabiola A Sánchez
Journal:  Circ Res       Date:  2016-07-08       Impact factor: 17.367

3.  Endothelial function predicts positive arterial-venous fistula remodeling in subjects with stage IV and V chronic kidney disease.

Authors:  Christopher D Owens; Nicole Wake; Ji Min Kim; Dirk Hentschel; Michael S Conte; Andres Schanzer
Journal:  J Vasc Access       Date:  2010 Oct-Dec       Impact factor: 2.283

Review 4.  Other than potency, are all statins the same?

Authors:  Nicola Abate; Manisha Chandalia
Journal:  Curr Atheroscler Rep       Date:  2006-01       Impact factor: 5.113

5.  A novel mechanism of action for statins against diabetes-induced oxidative stress.

Authors:  C Vecchione; M T Gentile; A Aretini; G Marino; R Poulet; A Maffei; F Passarelli; A Landolfi; A Vasta; G Lembo
Journal:  Diabetologia       Date:  2007-02-06       Impact factor: 10.122

6.  Atazanavir improves cardiometabolic measures but not vascular function in patients with long-standing type 1 diabetes mellitus.

Authors:  Jessica Milian; Allison B Goldfine; Jonah P Zuflacht; Caitlin Parmer; Joshua A Beckman
Journal:  Acta Diabetol       Date:  2015-01-08       Impact factor: 4.280

Review 7.  Is reversal of endothelial dysfunction still an attractive target in modern cardiology?

Authors:  Ify Mordi; Nikolaos Tzemos
Journal:  World J Cardiol       Date:  2014-08-26

Review 8.  Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.

Authors:  R Preston Mason
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study.

Authors:  Adefowope Odueyungbo; Marek Smieja; Lehana Thabane; Fiona Smaill; Kevin Gough; John Gill; Todd Anderson; Dawn Elston; Sandy Smith; Joseph Beyene; Eva Lonn
Journal:  AIDS Res Ther       Date:  2009-06-11       Impact factor: 2.250

Review 10.  Endothelial dysfunction as a target for prevention of cardiovascular disease.

Authors:  Daniele Versari; Elena Daghini; Agostino Virdis; Lorenzo Ghiadoni; Stefano Taddei
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.